NEWS

Achim Krauss, PhD, FAOPT is Chief Scientific Officer at RareSight, responsible for overseeing non-clinical drug development and driving the Company’s scientific and technical strategy.  He is also the Founder and Principal Consultant of Archer Ophthalmics, LLC, which provides support and consulting services for front-of-the-eye and retinal diseases to biotech and startup companies in ophthalmology.  

Most recently, Achim was the Founder, CEO and President of AxeroVision, where he advanced two ophthalmic drug candidates – licensed from GSK – from preclinical development through IND filing and clinical proof-of-concept for the treatment of dry eye disease.  In late 2022, AxeroVision was acquired by CS Pharmaceuticals, resulting in a successful exit.  

Previously, Achim held various leadership positions at GSK, Pfizer and Allergan establishing a consistent track record in ophthalmic drug discovery and development.  At GSK Ophthalmology, he was Director of Research, responsible for disease area strategy and programs in dry eye and glaucoma.  At Pfizer, his roles included Head of Ocular Biology, Ophthalmology Therapeutic Area Leader, Ophthalmology Portfolio, Strategy and External Alliances Lead and member of the Global Discovery Management Committee.  At Allergan, he was Principal Scientist with a primary focus on glaucoma research.  Achim was a key contributor to the glaucoma drugs LUMIGAN® (also marketed as LATISSE® for cosmetic use) and VYZULTA™.  

Achim is a Fellow of the Association for Ocular Pharmacology and Therapeutics where he served as President and on the Board of Directors for approximately 20 years.  He also serves on the editorial board of the Journal for Ocular Pharmacology and Therapeutics.  Achim is an author on more than 50 peer-reviewed scientific publications and an inventor on more than 20 granted patents. Achim earned a B.S. in Pharmacy and a Ph.D. (Dr. rer. nat.), graduating Magna cum Laude, from the University of Tübingen, Germany.